ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2026
Association between α-synuclein in plasma neuron-derived exosomes and clinical symptoms in Parkinson's disease.
Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeThe objective of this study was to investigate the association between α-synuclein (α-syn) levels in neuron-derived exosomes (NDEs) and the severity of motor and non-motor symptoms in Parkinson's disease (PD) patients, and to evaluate α-syn in plasma NDEs as a potential early diagnostic biomarker for PD.
methodsFifty-five patients with PD and thirty-three healthy controls (HCs) were enrolled in this study. Additionally, various rating scales were utilized to assess the clinical symptom severity of the PD patients. To quantify the levels of α-syn, we employed magnetic particle-based chemiluminescence immunoassays.
resultsCompared with HCs, plasma NDE α-syn levels were significantly higher (p < 0.001) in the PD group. After false discovery rate correction for multiple comparisons, plasma NDE α-syn levels remained significantly correlated with UPDRS-III, HAMA, MMSE, and SCOPA-AUT scores (all Q < 0.05). Receiver operating characteristic (ROC) curve analysis demonstrated the significance of α-syn in plasma NDEs for diagnosing early-stage PD. The area under the curve (AUC) for α-syn was found to be 0.732 (95% CI: 0.610–0.854, p < 0.01).
conclusionOur study preliminarily found that the α-syn levels in plasma NDEs were modestly correlated with the severity of motor and non-motor symptoms in PD. Additionally, measuring α-syn in plasma NDEs showed potential as an adjunctive biomarker for aiding in the early detection of PD.
Indexed as
Identifiers
41762319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.